Rezera seeks up to $217M in Nasdaq IPO, offering 16.7M shares at $11-$13; GSK to buy up to $25M

Biotech Rezera, formerly NodThera, is seeking up to $217 million in a Nasdaq IPO, offering 16.7 million shares at $11 to $13 each under ticker RZRA. GSK has indicated interest in buying up to $25 million of shares, about 10% of the company after the offering.

Detected & updated continuously · Source: Nebula